Public Release: 

Findings support shorter course of radiation therapy after breast lumpectomy

Journal of the National Cancer Institute

A shorter, more convenient course of radiation therapy after breast lumpectomy appears to be just as effective as the longer, more standard, regimen, according to new research appearing in the August 7 issue of the Journal of the National Cancer Institute.

Radiation therapy after a lumpectomy substantially reduces the risk of breast cancer recurrence. However, researchers have not come to a consensus about the most appropriate length of radiation therapy that a patient should receive. In the United States, radiation is delivered in smaller doses over a several weeks, but in the United Kingdom and Canada, larger doses of radiation are delivered over a shorter period of time.

To determine which strategy is most effective, Timothy Whelan, B.M., B.Ch., M.Sc., of the Hamilton Regional Cancer Centre in Ontario, and his colleagues compared breast cancer recurrence and cosmetic outcome among 1,234 women randomly assigned to receive either a more intensive course of radiation over 22 days or a less intensive regimen over 35 days. All of the women had undergone lumpectomies for invasive breast cancers that had not spread to the lymph nodes.

Nearly 6 years later, the shortened course did not result in increased recurrence of breast cancer or result in a worse cosmetic outcome. Local recurrence-free survival at five years was 97.2% in the group receiving a shorter course of therapy, compared with 96.8% in the group receiving an extended course of therapy. There was no difference in disease-free or overall survival. Further, the cosmetic outcome was similar and excellent or good in the majority of patients in both groups. Toxic effects from radiation, such as damage to the skin, were rare in both groups.

The authors note that these findings may have important implications. "A shorter fractionation schedule will lessen the burden of treatment for women, many of whom may also receive adjuvant chemotherapy, and will have important quality-of-life benefits with respect to convenience and less time away from home and work," they write.

In an accompanying editorial, Carolyn I. Sartor, M.D., and Joel E. Tepper, M.D., of the University of North Carolina School of Medicine, ask whether this study sets a new standard for adjuvant radiation for early-stage breast cancer. It may for some women, they say, but they caution that these results only apply to women who have small tumors that have been completely removed. For these women, they say, it may be possible to make therapy shorter, more convenient, and less expensive.


Contact: Christine Naugler, Cancer Care Ontario, (416) 971-9800, ext. 1605, fax: (416) 217-1249;

Editorial: Dianne Shaw, UNC Lineberger Comprehensive Cancer Center, (919) 966-5905, fax: (919) 966-9727;

Whelan T, MacKenzie R, Julian J, Levine M, Shelley W, Grimard L, et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst 2002;94:1143-50.

Editorial: Sartor C, Tepper J. Is less more?: Lessons in radiation schedules in breast cancer. J Natl Cancer Inst 2002;94:1114-5.

Attribution to the Journal of the National Cancer Institute is requested in all news coverage.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.